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Background: : In patients with coronary artery disease, the anti-ischemic effects of ranolazine, an inhibitor of the late sodium current (INa, L), are 
dose-dependent. In patients with long-QT syndrome 3 (LQT3) ranolazine causes a dose-dependent shortening of the QTc interval. We determined the 
relationship between QTc shortening in patients with LQT3 as a surrogate marker for inhibition of INa, L, and the anti-ischemic effects of ranolazine.
methods: We performed a post-hoc analysis of pharmacodynamic and pharmacokinetic data from: 1) a study of the effect of ranolazine to shorten 
the QTc interval in patients with LQT3 (n=5); and 2) a randomized double-blind crossover study of the effect of ranolazine on exercise-induced ST 
depression in patients with CAD (n=191)
results: The relationships between the concentration of ranolazine and QTc shortening in LQT3 and time to 1mm ST-segment depression in CAD 
were linear (R2=0.91 and 0.88 respectively; Figure 1A). Similar correlations were obtained for other anti-ischemic effects of ranolazine (exercise 
duration, time to angina, and maximum ST depression). Using equations of best fit, a direct and linear relationship between QTc shortening and time 
to 1mm ST-segment depression was obtained (Figure 1B).
conclusion: The linear correlation between the QTc interval shortening and the anti-ischemic effects of ranolazine support a common underlying 
mechanism of action, namely inhibition of late INa.
